Table 1.
Summary of some of the most promising drugs currently under investigation, with their target molecule and more promising diseases of application.
| Class of products | Drug name | Target | Malignancies showing promising results |
|---|---|---|---|
| Monoclonal antibodies (mAbs) |
Ipilimumab
Tremelimumab |
CTLA-4 | Melanoma*, Non-Hodgkin's lymphoma, prostate cancer, renal cell cancer |
| Rituximab | CD20 | B-cell lymphoproliferative malignances | |
| Alemtuzumab | CD52 | B-CLL | |
| Trastuzumab | HER2/neu | Breast cancer | |
|
Cetuximab
Panitumumab |
EGFR | CRC, head and neck cancer, and others | |
| Bevacizumab | VEGF | CRC, metastatic breast cancer, NSCLC, advanced/metastatic renal cell carcinoma | |
| Conjugated mAbs |
Tositumomab
Ibritumomab |
CD20 | B-cell lymphoproliferative malignances |
| Oncogene inhibitors | Plexxikon | BRAF | Melanoma |
| Vaccines | Sipuleucel-T | APC presenting prostatic antigens | Prostate cancer |
| TroVax | APC presenting 5T4 epitope | Advanced CRC, renal cell carcinoma, prostate cancer | |
| HSP90 inhibitors |
17-AAG
geldanamycin |
HSP90 | Various cancer |
Abbreviations used in the table:
APC: antigen presenting Cell,
B-CLL: B-cell chronic lymphocytic leukemia,
CRC: coloRectal carcinoma,
EGFR: epidermal growth factor Receptor,
HCC: hepatocellular carcinoma,
HSP90: heat shock protein 90,
NSCLC: non-small-cell lung carcinoma,
VEGF: vascular epidermal growth factor,
*This agent as most of the others may also be used in combination with TAA-based vaccines, cytokines, and chemotherapy.